BillionToOne

Biotech & Pharma

Website LinkedIn

BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible. Our proprietary molecular counting platform can accurately count DNA molecules at the single-count level to help improve disease detection.

Founded
2016
Company size
501-1K
Headquarters
Union City, California, US
Funding
Series D

Hiring activity

Open roles
29
Posted in the last 30 days
33

Updated 6h ago

What BillionToOne says about its culture

Achievement — work you can point at and feel proud ofwork you can point at and feel proud ofAchievementIndependence — room to make your own decisionsroom to make your own decisionsIndependenceRecognition — getting somewhere, and being recognized for itgetting somewhere, and being recognized for itRecognitionRelationships — colleagues you get on with, and work that helps peoplecolleagues you get on with, and work that helps peopleRelationshipsSupport — managers who back their people upmanagers who back their people upSupportWorking conditions — steady, well-run conditions you can rely onsteady, well-run conditions you can rely onWorkingconditions

What BillionToOne says it offers, drawn from its own website.

Check if you fit

Opens the career fit test.

We strive to remove the fear of the unknown by providing molecular diagnostics that are accurate, fast, and accessible.

  • Internally Motivated & Passionate

    “Internally Motivated & Passionate”Source

  • Kindly Inquisitive & Collaborative

    “Kindly Inquisitive & Collaborative”Source

They say people do well here who…

  • Intrinsically motivated and holds high personal standards even without oversight
  • Driven to do extraordinary work and generous enough to help others do the same
  • Collaborative, seeking genuine partnership where combined efforts exceed individual contributions

Quoted from BillionToOne's own website. TeaKo does not verify these claims.

Latest openings

29 open roles at BillionToOne. Members see each one.